Abstract: The present invention relates to a composition for preventing, improving, or treating diseases related to advanced glycation end products, comprising an indole derivative or a pharmaceutically acceptable salt thereof. Specifically, the composition of the present invention possesses the effect of trapping methylglyoxal (MGO), which is a main precursor of advanced glycation end products, and thus can be effectively used for preventing, improving, or treating diseases related to advanced glycation end products.

Abstract: The present invention relates to a novel indole derivative and a use thereof. The novel indole derivative according to the present invention traps methylglyoxal (MGO), which is a main precursor of advanced glycation end products, and thus can be effectively used for preventing, improving, or treating diseases related to advanced glycation end products.

Abstract: Disclosed are an organic alloy for an organic optoelectric device that is an organic alloy of at least two kinds of organic compounds, the at least two kinds of organic compounds includes a first organic compound and a second organic compound, a difference between evaporation temperatures of the first organic compound and the second organic compound is less than or equal to about 20° C. at less than or equal to about 10?3 torr, and a light emitting wavelength of the organic alloy is different from light emitting wavelengths of the first organic compound, the second organic compound, and a simple mixture of the first organic compound and the second organic compound, and an organic optoelectric device and a display device including the organic alloy.

Abstract: Disclosed are an organic alloy for an organic optoelectric device that is an organic alloy of at least two kinds of organic compounds, the at least two kinds of organic compounds includes a first organic compound and a second organic compound, a difference between evaporation temperatures of the first organic compound and the second organic compound is less than or equal to about 20° C. at less than or equal to about 10?3 torr, and a light emitting wavelength of the organic alloy is different from light emitting wavelengths of the first organic compound, the second organic compound, and a simple mixture of the first organic compound and the second organic compound, and an organic optoelectric device and a display device including the organic alloy.

Abstract: Disclosed are an organic alloy for an organic optoelectric device that is an organic alloy of at least two kinds of organic compounds, the at least two kinds of organic compounds includes a first organic compound and a second organic compound, a difference between evaporation temperatures of the first organic compound and the second organic compound is less than or equal to about 20° C. at less than or equal to about 10?3 torr, and a light emitting wavelength of the organic alloy is different from light emitting wavelengths of the first organic compound, the second organic compound, and a simple mixture of the first organic compound and the second organic compound, and an organic optoelectric device and a display device including the organic alloy.

Abstract: A method of producing human metabolites of simvastatin or lovastatin, and more particularly, a method of producing human metabolites of simvastatin and lovastatin by using bacterial cytochrome P450 BM3(CYP102A1) or mutants thereof, and a composition and kit therefor.

Abstract: Provided is a novel method for preparing metabolites of atorvastatin using bacterial cytochrome P450, and a composition therefor, and more particularly, a composition for preparing 2-hydroxylated product of 4-hydroxylated product from atorvastatin including bacterial cytochrome P 450 BM3 (CYP102A1), CYP102A1 mutants, and chimeras derived from the CYP102A1 mutants, a kit therefor, and a method for preparing thereof.

Abstract: Provided is a novel method for preparing metabolites of atorvastatin using bacterial cytochrome P450, and a composition therefor, and more particularly, a composition for preparing 2-hydroxylated product of 4-hydroxylated product from atorvastatin including bacterial cytochrome P 450 BM3 (CYP102A1), CYP102A1 mutants, and chimeras derived from the CYP102A1 mutants, a kit therefor, and a method for preparing thereof.

Abstract: A method of producing human metabolites of simvastatin or lovastatin, and more particularly, a method of producing human metabolites of simvastatin and lovastatin by using bacterial cytochrome P450 BM3(CYP102A1) or mutants thereof, and a composition and kit therefor.